Page 13 - மன இறுக்கம் ஸ்பெக்ட்ரம் கோளாறு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regencell Bioscience Holdings Limited announces pricing of approximately $21.9 million initial public offering 11 hours ago 11 hours ago ANTARA/Business Wire Hong Kong (Antara/Business Wire)- Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the pricing of its initial public offering (“Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 16, 2021 under the ticker symbol “RGC.”

New yorkUnited statesHong kongJames chungBrigid leeVicky leeYvonne leeEquity group incHunter taubman fischer liExchange commissionStrategic financial relationsMaxim groupRegencell bioscience holdingsRegencell bioscience holdings limitedBusiness wireBioscience holdings limited